CANCER: ADVANCED INSIGHTS INTO PATHOGENESIS, CLASSIFICATION, THERAPEUTIC STRATEGIES, AND PREVENTION

Jumanova Nargiza Eshmamatovna
Assistant teacher at Samarkand State Medical University
Farxodov Sharofiddin Shamsiddin o'g'li
Tursunmurodov Rustam Ravshan o‘g‘li
Abdumanonov Shahzod Yah'yo o'g'li
Primqulov Abdulla Akbarjonovich
Student of Samarkand State Medical University

Abstract: *Cancer is a heterogeneous disease characterized by uncontrolled proliferation, genomic instability, and interactions with the tumor microenvironment. It remains a leading cause of global mortality, with incidence rates projected to increase due to aging populations and environmental factors. This article provides a comprehensive analysis of cancer biology, emphasizing molecular mechanisms of carcinogenesis, cancer classification, innovative treatment approaches, and prevention strategies. Advances in precision oncology, artificial intelligence (AI)-driven diagnostics, and immunotherapy have revolutionized cancer care, yet challenges such as drug resistance, tumor heterogeneity, and metastasis persist. Addressing these obstacles requires an interdisciplinary approach combining molecular biology, computational modeling, and novel therapeutic interventions.*

Keywords: *Cancer, Oncogenesis, Tumor Microenvironment, Targeted Therapy, Immunotherapy, Chemotherapy, Precision Medicine, Epigenetics, Metastasis, Carcinogenesis, Checkpoint Inhibitors, Angiogenesis, Cancer Stem Cells, Liquid Biopsy, Tumor Heterogeneity, Drug Resistance, AI in Oncology, Tumor Metabolism*

Introduction. Cancer is one of the most complex and deadly diseases, affecting millions of people worldwide. According to the World Health Organization (WHO), it accounted for approximately 10 million deaths in 2023, making it the second leading cause of mortality globally. The increasing prevalence of cancer is attributed to multiple factors, including aging populations, exposure to carcinogens, genetic predisposition, and lifestyle choices.

Modern oncology research has significantly advanced our understanding of tumor biology, leading to the development of targeted therapies, immunotherapies, and early detection strategies. Despite these advancements, several challenges persist, including tumor heterogeneity, drug resistance, and immune evasion mechanisms. The hallmarks of cancer, initially defined by Hanahan and Weinberg, serve as a framework for understanding malignant transformation. These hallmarks include:

Sustained proliferative signaling

Evasion of growth suppressors
Resistance to apoptosis
Replicative immortality
Induction of angiogenesis
Activation of invasion and metastasis
Reprogramming of energy metabolism
Evasion of immune destruction
Tumor-promoting inflammation
Genome instability and mutation

This article delves into the molecular basis of cancer, its classification, therapeutic advances, and future directions in cancer research.

Molecular Mechanisms of Carcinogenesis

Genetic and Epigenetic Alterations

Cancer arises from cumulative genetic mutations and epigenetic modifications that disrupt normal cellular regulatory mechanisms.

Oncogenes and Tumor Suppressor Genes

Oncogenes: Mutations in genes like KRAS, MYC, and EGFR lead to uncontrolled proliferation.

Tumor Suppressor Genes: Loss-of-function mutations in TP53, RB1, and BRCA1/2 eliminate critical cell cycle checkpoints.

Epigenetic Modifications

DNA Methylation: Hypermethylation of tumor suppressor genes silences their expression, while hypomethylation of oncogenes enhances their activity.

Histone Modifications: Altered chromatin states influence gene transcription, promoting tumor progression.

MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs): These molecules regulate post-transcriptional gene expression, impacting cancer cell behavior.

Tumor Microenvironment (TME)

The TME consists of cancer cells, stromal cells, immune cells, extracellular matrix (ECM), and signaling molecules that support tumor survival and progression.

Hypoxia and Angiogenesis: Hypoxia-inducible factor 1-alpha (HIF-1α) promotes vascular endothelial growth factor (VEGF) secretion, leading to neovascularization.

Cancer-Associated Fibroblasts (CAFs): Secrete growth factors that promote tumor invasion.

Immune Evasion Mechanisms: Tumors exploit checkpoint proteins like PD-1/PD-L1 to suppress T-cell activity.

Metastasis and Invasion

Metastasis is responsible for over 90% of cancer-related deaths and involves multiple steps:

1. Epithelial-Mesenchymal Transition (EMT): Epithelial cells lose polarity and acquire migratory capabilities.

2. Invasion and Intravasation: Cancer cells invade surrounding tissue and enter circulation.

3. Circulating Tumor Cells (CTCs): Facilitate dissemination through the bloodstream.

4. Extravasation and Colonization: Tumor cells exit circulation and establish secondary tumors in distant organs.

Cancer Classification

Cancers are classified based on histological type, molecular features, and tissue of origin.

By Tissue of Origin

Carcinomas: Originating from epithelial cells (lung, breast, prostate, colorectal cancers).

Sarcomas: Arising from connective tissues (osteosarcoma, liposarcoma).

Leukemias and Lymphomas: Affecting blood and lymphatic tissues (acute lymphoblastic leukemia, Hodgkin's lymphoma).

Central Nervous System (CNS) Cancers: Glioblastomas and astrocytomas.

By Molecular Subtype

Breast Cancer: Luminal A/B, HER2-positive, and triple-negative breast cancer (TNBC).

Lung Cancer: EGFR-mutated, ALK-rearranged, KRAS-mutant subtypes.

REFERENCES:

1. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-674.

2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48.

3. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The global cancer burden. Cancer. 2021;127(16):3029-3030.

4. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.

5. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.

6. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanisms of immune evasion in cancer. Cell. 2016;165(1):23-35.

7. Ledford H. Liquid biopsy tests make big leap in cancer detection. Nature. 2022;611(7935):620-621.

8. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck.